Avastin use restricted

Bevacizumab blocks the action of VEGF, thus inhibiting angiogenesis
Bevacizumab blocks the action of VEGF, thus inhibiting angiogenesis

Use of bevacizumab (Avastin) in patients with metastatic breast cancer has been restricted to combination therapy with the taxane, paclitaxel.

The antibody was previously also licensed for use with another taxane, docetaxel. However, new data submitted to the Committee for Medicinal Products for Human Use showed that the combination of bevacizumab with docetaxel has a smaller effect on progression-free survival than previously thought, and may even reduce overall survival. Accordingly, use of this combination is no longer recommended.

The Committee concluded that the risk-benefit balance for combination use of bevacizumab with paclitaxel remains positive.

The other indications of Avastin, including non-small cell lung cancer, colorectal cancer and renal cell carcinoma, are unaffected by the change.

View Avastin drug record

Further information: Roche

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more